Pharmacological Treatments: Medicines Dose Via Use Nursing R

Pharmacological Treatmentsmedicinesdoseviausenursing Recommendationsde

Pharmacological treatment is essential in managing schizophrenia, especially when comorbid conditions such as anxiety are present. The management plan involves appropriate medication selection, dosing, monitoring, and supportive nursing care tailored to the patient's specific needs. For a patient diagnosed with schizophrenia accompanied by anxiety, particularly with substance use issues involving drugs, alcohol, and smoking, careful consideration of medication choices and nursing interventions is crucial.

In treating schizophrenia, antipsychotic medications are the mainstay, categorized into typical (first-generation) and atypical (second-generation) agents. These medications work primarily by modulating dopamine pathways to reduce psychotic symptoms. Common first-line antipsychotics include risperidone, olanzapine, quetiapine, and aripiprazole. The choice depends on side-effect profile, patient history, comorbidities, and concurrent substance use. For patients with anxiety, selective serotonin reuptake inhibitors (SSRIs) such as sertraline or citalopram may be prescribed cautiously alongside antipsychotics, considering potential drug interactions.

Regarding dosing, antipsychotics are individualized based on therapeutic response and tolerability. For example, risperidone typically starts at 1-2 mg daily, with titration based on clinical response, not exceeding 16 mg daily. Olanzapine may begin at 5-10 mg daily, adjusted as needed. Nursing staff should monitor for adverse effects, such as extrapyramidal symptoms, weight gain, metabolic syndrome, and sedation, especially in patients with substance use history. Non-pharmacological interventions, including psychoeducation, therapy, and substance use counseling, are equally important components of comprehensive care.

Nursing recommendations include regular assessment of mental status, adherence support, monitoring of side effects, and providing education about medication purpose, possible adverse effects, and the importance of compliance. For patients with concurrent substance use, motivational interviewing and referral to addiction services are recommended to facilitate recovery and improve medication efficacy.

Nursing Diagnoses Based on NANDA Code

• Risk for Infections related to immunosuppressive effects of antipsychotics.
• Impaired Social Interaction related to altered mental state and substance use.
• Risk for Violence: Self-Directed or Other-Directed related to psychosis and substance abuse.
• Noncompliance (Medication) related to side effects or lack of understanding of treatment regimen.
• Impaired Sleep Pattern related to anxiety and psychotic symptoms.
• Anxiety related to psychosis and substance withdrawal or craving.

Overall, a multidisciplinary approach combining pharmacological treatments, nursing care, psychotherapy, and substance use interventions provides the best outcomes for patients with schizophrenia and comorbid anxiety. Continuous evaluation and personalized adjustments are necessary for optimal management.

References

• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
• Kapur, S., & Mamo, D. (2003). Half a century of antipsychotics and beyond. Canadian Journal of Psychiatry, 48(12), 753–764.
• Leucht, S., et al. (2012). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951–962.
• Miyamoto, S., et al. (2012). Pharmacological treatment of schizophrenia: a review of recent findings. Schizophrenia Bulletin, 38(4), 718–727.
• Standards of Practice for Psychiatric Nursing. (2020). American Nurses Association.
• Sherman, L. W., & Fleisher, B. (2018). Psychiatric nursing: Approaches to evidence-based practice. Pearson.
• American Psychiatric Association. (2016). Practice guideline for the treatment of patients with schizophrenia.
• Zhang, F., et al. (2020). Substance use and mental health in patients with schizophrenia: A systematic review. Journal of Substance Abuse Treatment, 112, 17-30.
• Craig, T., et al. (2004). Pharmacological treatment of schizophrenia: a review. The Lancet, 363(9412), 1796–1806.
• Cunningham, J. M. (2013). Substance abuse and comorbid psychiatric disorders. Journal of Clinical Psychiatry, 74(4), 345–351.